Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Grown Up... © A Newsletter For Those Who Care For ADOLESCENTS, ADULTS, and AGING ADULTS AMYOTROPHIC LATERAL SCLEROSIS (ALS) Volume 16, Issue 6 June 2011 Editor-in-Chief: Mary Myers Dunlap, MAEd, RN BEHAVIORAL OBJECTIVES AFTER READING THIS NEWSLETTER THE LEARNER WILL BE ABLE TO: 1. Describe the pathophysiology, etiology, and clinical manifestations of ALS. 2. Discuss management of ALS, including implications for the healthcare provider. Amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, is a progressive, chronic neuromuscular disease that attacks nerve cells and pathways in the brain and spinal cord causing muscles to deteriorate. The affected nerves cells are those responsible for providing electrical stimulation to the muscles, which allows for voluntary movement. Without the necessary electrical stimulation, the muscles begin to atrophy and eventually become paralyzed. ALS is a terminal illness with death usually resulting in respiratory infections or complications. More than half of ALS patients die within 3 years of the first symptoms and 90% within 5 years. ALS was first described in 1869 by Jean-Martin Charcot. Lou Gehrig first brought national and international attention to the disease when he abruptly retired from the New York Yankees in 1939. Today, approximately 5,000 new cases of ALS are diagnosed each year in the United States. ALS usually occurs between 40 and 70 years of age, with the incidence increasing with each decade. The average age of onset is age 55. The male to female ratio is 1.3 to 1.5 but approaches 1 to 1 at ages older than 70 years. The disease has no racial, socioeconomic, or ethnic boundaries. This newsletter will describe the pathophysiology, etiology, and clinical manifestations of ALS. Management of ALS will be discussed, including implications for the healthcare provider. PATHOPHYSIOLOGY ALS causes progressive degeneration of the upper and lower motor neurons. Motor neurons are those cells in the brain, brain stem, and spinal cord that control voluntary movements of muscles. Upper motor neurons reside in the motor cortex of the brain and send electrical impulses to the lower motor neurons in the brain stem and spinal cord. Upper motor neurons are involved in the initiation and control of voluntary movements and the maintenance of muscle tone. When damaged or lost, the limbs become spastic or stiff, and over-activity of tendon reflexes, such as knee and ankle jerks, typically occurs. Lower motor neurons are the motor neurons connecting the brainstem and spinal cord to muscle fibers, bringing the nerve impulses from the upper motor neurons out to the muscles. Loss or damage of lower motor neurons results in weakness, twitching and atrophy of the muscles. Both sets of motor neurons are required for optimal control of muscles. When there are disruptions in these signals, the muscles do not work properly. Eventually, the ability to control voluntary movement can be lost. Indications of upper motor neuron involvement include tight and stiff muscles (spasticity) and exaggerated reflexes (hyperreflexia) including an overactive gag reflex. A positive Babinski's sign, the big toe extends upward and other toes spread out, also indicates upper motor neuron damage. Manifestations of lower motor neuron degeneration include muscle weakness and atrophy, muscle cramps, fleeting twitches of muscles that can be seen under the skin (fasciculations) and depressed tendon reflexes. To be diagnosed with ALS, patients must have signs and symptoms of both upper and lower motor neuron damage that cannot be attributed to other causes. ETIOLOGY Genetics accounts for 5–10% of cases of familial ALS (FALS) in the United States. A recessive dominant trait is responsible for FALS, meaning only one parent carries the gene. Children of patients with this type of ALS, have a 50% chance of developing the disease. In 90 – 95% of cases, ALS occurs sporadically. Although no cause and effect has been found, U.S. veterans and laborers engaged in agricultural work, factory work, heavy manual labor, and welding are groups of people who appear to develop ALS more often than the general population. Current research suggests that glutamate, the most important neurotransmitter for healthy brain function, accumulates to toxic levels at the synapses with ALS, causing degeneration of neurons. Neurotransmitters are the chemicals which allow the transmission of signals from one neuron to the next across synapses. Excessive levels of glutamate can over stimulate motor neurons and cause them to die. Copyright © 2011 Growing Up With Us, Inc. All rights reserved. Page 1 of 4 CLINICAL MANIFESTATIONS ALS involves a slow, chronic progression of symptoms. The onset of symptoms varies with each patient. Regardless of the part of the body first affected by ALS, symptoms spread to other parts of the body as the disease progresses. Occasionally, the symptoms remain confined to one limb for a long period of time or for the whole length of the illness. This is known as monomelic amyotrophy. The majority of people with ALS experience "limb onset" ALS. One of the first symptoms is usually unexplained weakness in a limb. The first symptoms may involve the arms, in which patients may experience difficulty with tasks requiring manual dexterity, such as buttoning a shirt, writing, or turning a key in a lock. Patients with the leg-onset form may experience awkwardness when walking or running. Or they may notice incidents of tripping or stumbling, often with a "dropped foot" which drags gently along the ground. Early in the disease one limb is usually involved, and later in the course of the illness the other limbs become involved. It’s important to note that upper limb symptoms do not mean upper motor neuron involvement, and that involvement of the legs is not synonymous with lower motor neuron loss or damage. About 25% of ALS cases are "bulbar onset”, in which the oral muscles degenerate. These patients first notice difficulty speaking clearly or swallowing. Speech may become slurred, nasal in character, or quieter than normal. Other symptoms include hoarseness, difficulty swallowing (dysphagia), and loss of tongue mobility. Bulbar palsy is one of the most distressing features of motor neuron disease. It causes weakness of the tongue, pharynx, and facial muscles and leads to loss of salivary control. The patient has difficulty with eating and may choke and drool. A smaller proportion of patients experience "respiratory onset" ALS where the intercostal muscles that support breathing are affected first. Death can occur within months with this type of onset. Early respiratory or bulbar symptoms and increasing age are poor prognostic indicators. Many patients with ALS experience involuntary emotional expression disorder (IEED), also known as pseudobulbar affect or emotional lability. IEED is characterized by episodes of uncontrollable laughter, crying or smiling, that are inappropriate and independent of the patient’s mood. IEED is attributable to degeneration of upper motor neurons resulting in exaggeration of motor expressions of emotion. Mood swings, anxiety, and depression may also occur. As the patient watches muscle strength decline, becomes increasingly dependent on others, and faces their own mortality, feelings of depression commonly increase and suicidal thoughts may emerge. Rarely is there cognitive involvement associated with ALS. Bladder or bowel function, as well as the senses of vision, touch, hearing, taste, and smell, are not affected. As the disease progresses more muscle groups become involved. However, with ALS, all muscles aren’t involved. For example, the cardiac muscles, as well as the smooth muscles (those in the hollow parts of the body, such as in the stomach, intestines, blood vessels and the bladder), aren't involved in ALS. DIAGNOSIS The patient usually adapts to the initial, gradual changes in muscle strength and endurance associated with ALS before consulting a physician / neurologist. Often these symptoms are initially attributed to aging. However, over time the patient or a family member realizes that frequent tripping or falling, the inability to hold a full cup of coffee or dress oneself, and/or slowed speech is likely something more than aging. There is no definitive test for diagnosing ALS. A neurologic exam, assessment of patient symptoms, and family history are important parts of the diagnosis. Both upper and lower neuron impairment must be present for the diagnosis of ALS to be made, including tight and stiff muscles and exaggerated reflexes (upper neuron involvement) and muscle weakness, wasting, twitching, and cramps (lower neuron involvement). Diagnostic tests frequently include blood studies, electromyography (EMG), nerve conduction velocities (NCV), x-rays, muscle and/or nerve biopsy, CT scan, and magnetic resonance imaging (MRI). Often times, these tests rule out other disorders that mimic symptoms of ALS, such as myasthenia gravis, multiple sclerosis, and multifocal motor neuropathy (MMN). Genetic testing may be conducted if there is a family history of ALS. PATIENT CARE PRIORITIES Riluzole (Rilutek), which reduces the presynaptic release of glutamate and protects neurons by reducing excitotoxicity, is the only FDA approved drug for ALS patients. Treatment should be initiated as early as poss ible after the patient has been diagnosed. Liver function should be closely monitored, since it causes an elevation in liver enzymes. Other medications may be prescribed according to the patient’s symptoms, such as Baclofen (Lioresal) to relieve stiffness in the limbs and Tizanidine, a muscle relaxant, for treatment of muscle spasms. Meeting the nutritional needs of patients with ALS is priority. Patients with ALS have a high risk of malnutrition. Drooling and thick mucus can cause choking and interfere with eating. Suctioning is a key intervention. The patient should be fed small, frequent high-calorie meals. The head of the bed should be elevated 30 minutes after meals to help prevent possible aspiration. As the disease progresses, nutritional support is commonly provided by a gastrostomy tube. There is no cure for ALS. Patients are cared for symptomatically, and supportive management is directed at preventing complications of immobility, including skin breakdown and deep vein thrombosis. Most patients with ALS are cared for at home. Patient and family teaching, as well as support, are essential roles of the healthcare professional. Growing Up With Us, Inc. PO Box 481810 • Charlotte, NC • 28269 Phone: (919) 489-1238 Fax: (919) 321-0789 Editor-in-Chief: Mary M. Dunlap MAEd, RN E-mail: editor@growingupwithus.com Website: www.growingupwithus.com GUWU Testing Center www.growingupwithus.com/quiztaker/ Copyright © 2011 Growing Up With Us, Inc. All rights reserved. Page 2 of 4 Name:_____________________________________________________ Date:___________________________________ Employee ID#:____________________________________________ Unit:____________________________________ POPULATION/AGE-SPECIFIC EDUCATION POST TEST GROWN UP... Caring For Adolescents, Adults, and Aging Adults June 2011 Competency: Demonstrates Age-Specific Competency by correctly answering 9 out of 10 questions related to Amytrophic Lateral Sclerosis (ALS). AMYOTROPHIC LATERAL SCLEROSIS (ALS) 1. One of the first symptoms of ALS is often: a. b. c. d. dysphagia. emotional lability. muscle cramps and wasting. unexplained weakness in a limb. 2. ALS eventually leads to atrophy of the involuntary muscles. a. True b. False 3. ALS involves eventual degeneration of the brain and meninges. a. True b. False 4. Which statement is true about ALS? It: a. b. c. d. involves both the upper and lower motor neurons. is an acute condition. affects women more often than men. has an average age of onset at age 45. 5. Indicators of lower neuron involvement in ALS include: a. b. c. d. muscle cramps and fasciculations. tight and stiff muscles. positive Babinski. exaggerated reflexes. Copyright © 2011 Growing Up With Us, Inc. All rights reserved. Page 3 of 4 Name:_____________________________________________________ Date:___________________________________ Employee ID#:____________________________________________ Unit:____________________________________ POPULATION/AGE-SPECIFIC EDUCATION POST TEST GROWN UP... Caring For Adolescents, Adults, and Aging Adults AMYOTROPHIC LATERAL SCLEROSIS (ALS) 6. Current research indicates which of the following accumulates to toxic levels with ALS? a. b. c. d. Serotonin Histamine Dopamine Glutamate 7. Symptoms of ALS typically include which of the following? a. b. c. d. Depression Cognitive loss Bowel and bladder dysfunction Loss of the senses 8. The only FDA approved drug for ALS is Riluzole (Rilutek). a. True b. False 9. Which statement is NOT true about diagnosing ALS? ALS: a. b. c. d. has a hereditary component in some cases. symptoms are often initially attributed to aging by the patient. is often diagnosed by ruling out other conditions. affects those under 50 years old most commonly. 10. After the appearance of the first symptoms of ALS, life expectancy rarely exceeds how many years? a. b. c. d. 1 3 5 7 Copyright © 2011 Growing Up With Us, Inc. All rights reserved. Page 4 of 4